Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
28.1M
-
Shares change
-
+1.87M
-
Total reported value, excl. options
-
$53.1M
-
Value change
-
+$4M
-
Number of buys
-
28
-
Number of sells
-
-33
-
Price
-
$1.89
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q4 2019
81 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q4 2019.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.1M shares
of 108M outstanding shares and own 25.96% of the company stock.
Largest 10 shareholders include MFN Partners Management, LP (4M shares), RENAISSANCE TECHNOLOGIES LLC (2.78M shares), MORGAN STANLEY (2.52M shares), EcoR1 Capital, LLC (2.09M shares), Endurant Capital Management LP (2.06M shares), Sofinnova Investments, Inc. (1.91M shares), Broadfin Capital, LLC (1.89M shares), Rock Springs Capital Management LP (1.6M shares), VANGUARD GROUP INC (1.41M shares), and Man Group plc (1.3M shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.